JA3-WP4

Home  /  Outputs   /  JA3-WP4 (Page 4)

Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on Regorafenib (Stivarga©) The purpose of the assessment is to evaluate Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously

Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on midostaurin (Rydapt©) This is the assessment of the relative effectiveness of midostaurin (Rydapt©) in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy for patients in

Sudden cardiac arrest (SCA) is the most common cause of death in patients with coronary artery disease. Mostly, ventricular tachycardia and ventricular fibrillation are the underlying aetiology of SCA, which is claimed to be successfully treated by a novel defibrillation